CPT Code: 83704
Order Code: 37847
Includes: LDL Particle Number (LDL-P), Small LDL Particle Number (Small LDL-P), LDL Size, HDL Particle Number (HDL-P), Large HDL Particle Number (Large HDL-P), HDL Size, Large VLDL Particle Number (Large VLDL-P), VLDL Size
ABN Requirement: No
Specimen: Serum
Volume: 2.0 mL
Minimum Volume: 1.0 mL
Container: Red Top (no gel barrier) tube
Collection:
- Collect and label sample according to standard protocols.
- Gently invert tube 5 times immediately after draw. DO NOT SHAKE.
- Allow blood to clot 30-60 minutes.
- Centrifuge for 10 minutes.
- Aliquot serum into a labeled transport tube labeled as “Red Top Serum” and cap tightly.
- Store and transport refrigerated. It is acceptable to store frozen and ship refrigerated. Do not ship frozen on dry ice.
Fasting: Patient should be fasting 12 hours.
Transport: Store serum at 2°C to 8°C after collection and ship the same day per packaging instructions included with the provided shipping box.
Stability:
Ambient (15-25°C): Unacceptable
Refrigerated (2-8°C): 7 days
Frozen (-20°C): 10 days
Deep Frozen (-70°C): 28 days
Causes for Rejection: Specimens other than serum; improper labeling; samples not stored properly; samples older than stability limits; gross hemolysis; gross lipemia; serum collected using a gel barrier tube
Methodology: Nuclear Magnetic Resonance (NMR)
Turn Around Time: 3 days
Relative Risk Range:
| Test | Reference Range | Low | Relative Risk Range Moderate | High |
|---|---|---|---|---|
| LDL-P (nmol/L) | 592-2404 | <935 | 935-1816 | >1816 |
| Small LDL-P (nmol/L) | <1408 | <467 | 467-820 | >820 |
| LDL Size (nm) | 20.0-22.3 | >20.5 | N/A | ≤20.5 |
| HDL-P (µmol/L) | 21.1-43.4 | >32.8 | 29.2-32.8 | <29.2 |
| Large HDL-P (µmol/L) | >3.5 | >7.2 | 5.3-7.2 | <5.3 |
| HDL Size (nm) | 8.3-10.5 | >9.0 | 8.7-9.0 | <8.7 |
| Large VLDL-P (nmol/L) | <16.0 | <3.7 | 3.7-6.1 | >6.1 |
| VLDL Size (nm) | 41.1-61.7 | <47.1 | 47.1-49.0 | >49.0 |
Clinical Significance: The Lipoprotein Fractionation NMR test is used to help assess the risk for cardiovascular disease (CVD) in patients with intermediate or high risk based on traditional or emerging risk factors, and to assess therapeutic response in patients undergoing lipid-lowering therapy, by quantification of the number and size of lipoprotein particles.
The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.